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Abstract Ulcerative colitis (UC) is a chronic idiopathic
inflammatory disorder in which patients cycle between
active disease and remission. Budesonide multi-matrix
(MMX) is an oral second-generation corticosteroid
designed to deliver active drug throughout the colon. In
pharmacokinetic studies, the mean relative absorption of
budesonide in the region between the ascending colon and
the descending/sigmoid colon was 95.9 %. In 2 identically
designed, phase 3 studies (CORE I and II), budesonide
MMX 9 mg once daily was efficacious and well tolerated
for induction of remission of mild to moderate UC. Clinical
and endoscopic remission rates were 17.9 % (CORE I) and
17.4 % (CORE II) for budesonide MMX 9 mg compared
with 7.4 and 4.5 %, respectively, with placebo (p\ 0.05,
budesonide MMX 9 mg vs. placebo in both studies),
12.1 % with mesalamine 2.4 g, and 12.6 % with budes-
onide controlled ileal release capsules 9 mg. A 12-month
maintenance therapy study suggested that budesonide
MMX 6 mg may prolong time to clinical relapse: Median
time was [1 year with budesonide MMX 6 mg versus
181 days (p = 0.02) with placebo; however, further studies
are needed. In the CORE studies, budesonide MMX
exhibited a favorable safety profile; the majority of adverse
events were mild or moderate in intensity, and serious
adverse events were uncommon. Furthermore, rates of
potential glucocorticoid-related adverse events were com-
parable across treatment groups. The long-term (12-month)
safety of budesonide MMX appears to be comparable with
placebo. Data support budesonide MMX in the manage-
ment algorithm of UC.
Keywords Budesonide MMX  Induction therapy 
Remission  Ulcerative colitis
Introduction
Ulcerative colitis (UC) is a chronic idiopathic inflamma-
tory disorder involving the colonic mucosa. It is charac-
terized by periods of active symptomatic disease
interspersed with periods of clinical remission [1]. A 2012
systematic review indicated worldwide UC prevalence
rates of up to 249 per 100,000 persons in North America
and 505 per 100,000 persons in Europe; the highest
reported annual incidence rates of UC were 19.2 per
100,000 person-years in North America and 24.3 per
100,000 person-years in Europe [2]. The highest incidence
appears to occur during the age range of 20–30 years,
although there is some evidence for a second peak in
incidence later in life [2].
Endoscopic examination of the colon in patients with
UC reveals a number of characteristic changes seen in the
mucosa, including loss of vascular pattern, erythema,
granularity, friability, erosions, and ulceration [1, 3].
Mucosal healing, which has been defined as complete
resolution of the visible alterations or lesions, regardless of
their baseline nature or severity, is emerging as an
important goal in the management of inflammatory bowel
diseases such as UC; increasing evidence indicates that
mucosal healing is associated with reductions in the num-
ber of disease flares, hospitalizations, and the need for
colectomy in patients with UC [4].
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Classic symptoms of UC include rectal bleeding, diar-
rhea, urgency, tenesmus, and abdominal pain [1], and these
can impose a substantial burden on patients. Patients with
UC report problems in a number of aspects of their daily
lives, including withdrawal from social situations,
employment disruption, increased anxiety, and decrease in
health-related quality of life [5–7].
Current US [8] and European [9] guidelines recommend
treatment with 5-aminosalicylates (5-ASAs) as first-line
therapy for the induction of remission in patients with mild
to moderate UC; such treatment is considered most effec-
tive when combinations of both topical and oral prepara-
tions are used [8, 9]. Corticosteroids may be indicated in
patients in whom 5-ASA formulations are ineffective in
inducing remission [8, 9]. However, first-generation corti-
costeroids, such as prednisone, are associated with a
number of potential safety concerns, including increased
risks of serious infections, bone disease, the development
of cushingoid features, and increased risk of mortality [8,
10–12].
Budesonide is an orally active, second-generation cor-
ticosteroid that has affinity for the glucocorticoid receptor
approximately 8.5-fold, 15-fold, and 195-fold greater than
those of dexamethasone [13], prednisolone [14], and
hydrocortisone [14], respectively. A number of oral for-
mulations are available, including oral budesonide con-
trolled ileocolonic release (CIR) (Entocort EC,
AstraZeneca LP, Wilmington, DE), budesonide capsules
[Budenofalk capsules, Dr Falk Pharma, Freiburg, Ger-
many (not available in the USA)], and budesonide multi-
matrix (MMX; Santarus, Inc.; Raleigh, NC). Budesonide
CIR and budesonide capsules are not indicated for UC, but
are indicated only for induction of remission of mild to
moderate Crohn’s disease (CD) involving the ileum and/or
ascending colon; budesonide CIR is also indicated for
maintenance of CD remission. However, budesonide MMX
is indicated for induction of remission of mild to moderate
UC. Based on data from the Colonic Release Budesonide
(CORE) I and II studies [15, 16], which are described later
in this review, an updated UC treatment algorithm has
recommended budesonide MMX before the introduction of
conventional corticosteroids for the induction of remission
in patients for whom 5-ASA therapy has been unsuccess-
ful, or for those who relapse during 5-ASA therapy [10].
Several guidelines, developed before the availability of
budesonide MMX, do not recommend oral conventional or
second-generation corticosteroids for the maintenance of
remission in UC [8, 9]; however, data are accumulating to
support an acceptable tolerability profile for second-gen-
eration corticosteroids. One study, which evaluated the
long-term (1-year) safety of budesonide MMX in patients
with UC, indicated that oral budesonide MMX 6 mg had a
safety profile similar to that of placebo [17]. In addition,
the CD clinical trials of budesonide CIR and budesonide
capsules support the safety of oral budesonide during long-
term (e.g., 1 year) exposure in patients with inflammatory
bowel disease [18–28]. This article reviews the efficacy
and safety profile of budesonide MMX for the treatment of
UC.
Pharmacokinetic Properties of Budesonide
Budesonide is a second-generation corticosteroid with low
systemic bioavailability after oral administration because
of extensive (*90 %) first-pass hepatic metabolism [29]. It
is metabolized predominantly by hepatic cytochrome P450
3A (CYP3A) enzymes to form 2 principal metabolites:
16a-hydroxyprednisolone and 6b-hydroxybudesonide [30].
These metabolites comprise only 1–10 % of the biologic
activity of the parent compound [29]. Following oral
administration, approximately 75 % of the dose is excreted
in the urine and feces [29].
The MMX formulation has been designed to target
orally administered drugs to sites in the distal colon [31].
This delivery system utilizes an outer pH-dependent coat-
ing consisting of a hydrophilic and inert polymer matrix,
which allows passage of active drug through the gastroin-
testinal tract to the ileum, where the outer layer of the
capsule begins to dissolve at a pH[ 7.0. The active drug is
therefore delivered uniformly throughout the length of the
colon, thus minimizing systemic absorption, in contrast to
conventional corticosteroid absorption (Fig. 1) [31, 32].
MMX technology has been used effectively for the deliv-
ery of 5-ASA to the colon, whereby mesalamine MMX is
being used for both induction [31, 33–35] and maintenance
[36, 37] of remission in patients with mild to moderate UC.
In pharmacokinetic studies with budesonide MMX
9 mg, the mean relative absorption of budesonide in the
region between the ascending colon and the descending/
sigmoid colon was 95.9 % with drug detected between 4
and[24 h postdose (Fig. 2) [38]. This relative absorption
profile contrasts with the absorption of other oral budes-
onide formulations: For example, following administration
of budesonide CIR, approximately 69 % of the dose is
absorbed in the distal ileum and ascending colon, the sites
typically affected by inflammation in patients with CD
[39]. Release of the active drug from budesonide CIR and
budesonide capsules occurs in a more acidic environment
than with budesonide MMX, with absorption beginning at
pH values of 5.5 and 6.4, respectively [40, 41].
In a study of healthy volunteers, the mean lag time (tlag)
between administration of budesonide MMX 9 mg and
detection of budesonide in plasma was 6.8 h; the mean peak
plasma concentration (Cmax) was 1768.7 pg/mL, and the
time to Cmax (tmax) was 14.0 h [38]. Administration of
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budesonideMMXwith food resulted in significant decreases
in both Cmax (p = 0.03) and systemic exposure as measured
by the area under the concentration–time curve to 48 h
(AUC48h; p = 0.008), but these changes are not considered
to be clinically meaningful [38]; hence, budesonide MMX
may be administered with or without food [42]. After single
dosing in healthy volunteers, Cmax, AUC0–36 h, AUC0–?,
and half-life (t1/2) of budesonide MMX 9 mg were compa-
rable to those of budesonide CIR 9 mg [43]. Median tlag was
6 h for both 9- and 6-mg doses of budesonide MMX,
compared with 1 h for budesonide CIR 9 mg [43].
Because budesonide is metabolized predominantly in
the liver, bioavailability may be increased in patients with
impaired liver function. In a study in patients with primary
biliary cirrhosis who received a single dose of budesonide
3 mg (non-MMX formulation), patients with late-stage
(stage IV) disease showed significantly greater systemic
exposure to budesonide than those patients with early-stage
(stage I–II) disease [44]. Mean Cmax was 1.5 ng/mL in
patients with early-stage disease, compared with 4.9 ng/mL
in patients with late-stage disease (p\ 0.05), while mean
AUC0-? values were 5.1 and 23.2 h ng/mL (p\ 0.01),
respectively. Median t1/2 was also numerically higher in
patients with late-stage disease than in those with early-
stage disease (5.8 vs. 2.3 h, respectively), but this differ-
ence was not statistically significant [44]. In addition,
multiple dosing resulted in a significant increase in
AUC0–8 h at day 21 in patients with late-stage primary
biliary cirrhosis compared with early-stage primary biliary
cirrhosis (14.0 vs. 5.0 h ng/mL, respectively; p\ 0.05)
[44]. For this reason, patients with hepatic impairment who
are receiving treatment with budesonide MMX should be
monitored for symptoms of hypercorticism [42].
A drawback of corticosteroid treatment is decreased
drug accumulation in many patients, possibly resulting
Fig. 1 Targeted delivery of
budesonide MMX throughout
the colon. Original art from
Asklepios Medical Atlas/
Science Photo Library
Fig. 2 Scintigraphic image in a healthy volunteer showing dispersion
of [153Sm]-labeled budesonide MMX in the colon. The image was
obtained approximately 7 h after administration. Reprinted with
permission from Brunner et al. [38]
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from polymorphisms in the multidrug resistance 1 (MDR1)
gene [45, 46]. This phenomenon may result in the so-called
glucocorticosteroid resistance and subsequent failure of
patients to respond to therapy; data show that up to one-
sixth of UC patients may be steroid resistant [45, 46].
However, in a study of healthy volunteers or patients with
early-stage primary biliary cirrhosis, there were no appre-
ciable differences in Cmax or AUC and, thus, drug dispo-
sition, following administration of budesonide 3 mg (non-
MMX formulation) between individuals who were
homozygous for 2 common single nucleotide polymor-
phisms of the MDR1 gene [45].
Budesonide MMX for the Treatment of UC
Budesonide MMX for the Induction of Remission
of UC
The efficacy and safety of budesonide MMX for the
induction of remission in patients with mild to moderate
UC [UC disease activity index (UCDAI) score 4–10] have
been investigated in 2 identically designed, randomized
trials: CORE I and II (Table 1) [15–17, 47]. CORE I
compared budesonide MMX 9 mg and 6 mg with mesa-
lamine 2.4 g and placebo, whereas CORE II compared the
same doses of budesonide MMX with budesonide CIR
9 mg and placebo. In both studies, treatment was admin-
istered for 8 weeks, and the primary endpoint was clinical
and endoscopic remission at week 8. Remission was
defined as a UCDAI score B1, with scores of 0 for rectal
bleeding and stool frequency, no mucosal friability on
colonoscopy, and a reduction of C1 point in endoscopic
index score from baseline [15, 16].
In both studies, clinical and endoscopic remission was
achieved in a significantly greater percentage of patients
receiving budesonide MMX 9 mg compared with placebo
(Table 1). In CORE I, remission at week 8 was achieved in
17.9 % of patients receiving budesonide MMX 9 mg,
compared with 7.4 % (p = 0.01) in the placebo group and
12.1 % in the group receiving mesalamine (Fig. 3a) [15].
In CORE II, the 8-week remission rate was 17.4 % in
patients receiving budesonide MMX 9 mg, compared with
4.5 (p = 0.005) and 12.6 % (p = 0.048) in the placebo and
budesonide CIR groups, respectively (Fig. 3b) [16]. In
addition, a subgroup analysis in the CORE II study showed
that a significantly greater percentage of patients with left-
sided UC achieved clinical and endoscopic remission with
budesonide MMX 9 mg than with placebo (17.7 vs. 5.8 %,
respectively; p = 0.03); the percentage of patients with
extensive disease who reached clinical and endoscopic
remission was also numerically higher with budesonide
MMX 9 mg than with placebo (13.8 vs. 0 %, respectively),
but this difference was not statistically significant
(p = 0.10) [16].
In CORE I, an analysis by disease severity subgroup
indicated that in patients with mild UC (UCDAI score 4 or
5) who received budesonide MMX 9 mg or placebo, clin-
ical improvement (defined as a C3-point reduction in
UCDAI score) was achieved in 44.4 and 25.0 % of
patients, respectively; corresponding figures in patients
with moderate disease (UCDAI score C6 and B10) were
39.7 and 30.1 %, respectively. Furthermore, the mucosal
healing rate was greater with budesonide MMX 9 mg than
with placebo in patients with proctosigmoiditis (32.4 vs.
19.5 %, respectively; p = 0.20) and left-sided UC (40.6 vs.
26.5 %, respectively; p = 0.22). A similar numeric dif-
ference favoring budesonide MMX 9 mg was also
observed in patients with extensive UC (16.1 vs. 10.0 %
with placebo), but this difference also was not statistically
significant (p = 0.39) [15].
In a pooled analysis of the CORE I and CORE II studies
[47], patients treated with budesonide MMX 9 mg were at
least 3 times more likely to achieve clinical and endoscopic
remission versus placebo [OR 3.3 (95 % CI 1.7–6.4)] [47].
Budesonide MMX 9 mg was statistically significantly
more efficacious versus placebo for several subgroups:
males, females, patients B60 years, patients with prior
mesalamine use, patients without prior mesalamine use,
patients with mild UC at baseline, patients with moderate
UC at baseline, patients with proctosigmoiditis, patients
with left-sided UC, patients with UC duration [1 to
B5 years, and patients with UC duration[5 years.
Budesonide MMX for the Maintenance of Remission
of UC
The efficacy of budesonide MMX for the maintenance of
UC remission was investigated in a study of patients who
had achieved clinical and endoscopic remission in the
CORE I and II studies [15, 16] or patients in CORE I and II
who had received an additional 8 weeks of treatment
(budesonide MMX 9 mg) in an open-label study (Table 1)
[17, 48]. In the maintenance study, patients were ran-
domized to receive budesonide MMX 6 mg or placebo for
up to 12 months; the primary efficacy endpoint was clinical
remission, assessed after 1, 3, 6, 9, and 12 months. The
median time to clinical relapse (defined as rectal bleeding,
stool frequency C1–2 stools per day, or both) was 181 days
in the placebo group, but was not reached in the budes-
onide MMX group (p = 0.02; Fig. 4) [17]; at 12 months,
the probability of relapse was 59.7 and 40.9 %, respec-
tively [17]. However, the percentage of patients in whom
remission was maintained for up to 12 months did not
differ significantly between the groups, a finding that was
potentially attributable to insufficient statistical power.
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Therefore, the potential benefit of budesonide MMX in
maintenance of remission is currently unclear and further
studies are required.
Adverse Effects
In general, the budesonide molecule exhibits a more
favorable safety profile than first-generation oral cortico-
steroids such as prednisone or prednisolone. For example,
in a 10-week, double-blind, double-dummy study in 176
patients with CD who received tapering doses of pred-
nisolone or budesonide CIR for 10 weeks, the incidence of
glucocorticoid-related adverse effects was significantly
lower with budesonide than with prednisolone (33 vs.
55 %, respectively; p = 0.003). In addition, suppression of
the hypothalamic–pituitary–adrenal axis, assessed by
measurement of the mean morning plasma cortisol con-
centration, was significantly greater with prednisolone than
with budesonide CIR after 4 weeks (p\ 0.001) and
8 weeks (p = 0.02) [49].
The favorable adverse event (AE) profile of budesonide
MMX in UC patients was demonstrated in the CORE I and
II studies [15, 16]. The incidence of AEs in patients
receiving budesonide MMX 9 mg or 6 mg was 57.5 and
58.7 %, respectively, in CORE I, and 55.5 and 62.5 %,
respectively, in CORE II. In both studies, the majority of
AEs were mild or moderate in intensity, and the incidence
of serious AEs was low and similar across all treatment
groups. The most commonly reported AEs in patients
receiving budesonide MMX were UC, headache, and
nausea (Table 2) [15, 16]. In a pooled analysis of CORE I
and II, the incidence rates of predefined potential gluco-
corticoid-related adverse effects (acne, fluid retention,
flushing, hirsutism, insomnia, mood changes, moon face,
sleep changes, striae rubrae) were comparable for budes-
onide MMX 9 mg (10.2 %), 6 mg (7.5 %), and placebo
(10.5 %) [42]. The most common predefined potential
glucocorticoid-related adverse effects with budesonide
MMX 9 mg versus placebo were mood changes (3.5 vs.
4.3 %, respectively) and sleep changes (2.7 vs. 4.7 %,
respectively) [42]. In the 1-year budesonide MMX 6 mg
maintenance study, the safety profile of budesonide MMX
was comparable to that of placebo [17].
Pharmacoeconomics of UC
The chronic and relapsing nature of UC means that the
condition imposes a substantial burden on healthcare
resources, and this burden extends to society as a whole
Fig. 3 Combined clinical and endoscopic remission rates at week 8
in the CORE I (a) and CORE II (b) studies. Clinical and endoscopic
remission was defined as a UCDAI score B1, with scores of 0 for
rectal bleeding and stool frequency, no mucosal friability on
colonoscopy, and a reduction from baseline of C1 point in endoscopic
index score. CI confidence interval, CIR controlled ileal release.
Reprinted with permission from Sandborn et al. [15] and Travis et al.
[16]
Fig. 4 Kaplan–Meier plot showing the time to clinical relapse
(defined as rectal bleeding, stool frequency C1–2 stools per day
above normal, or both) in patients receiving maintenance therapy with
budesonide MMX 6 mg or placebo for up to 1 year [17]. Reprinted
with permission from Sandborn et al. [17]
366 Dig Dis Sci (2016) 61:358–370
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when indirect costs resulting from lost productivity are
taken into account. One US study estimated that the direct
medical costs of UC were $2.7 billion [50], with health
insurer and patient out-of-pocket expenditures between
$390 million and $920 million [51]. Another study reported
that mean estimated annual healthcare insurer expenditures
were significantly greater for patients with UC than for
patients without UC ($7424 vs. $4530, respectively,
p\ 0.001; expenditures adjusted to 2010 US dollars) [51],
and that mean annual out-of-pocket costs for UC patients
were $1280 [51].
Treatments that increase the likelihood of achieving and
maintaining remission in UC may provide cost savings
through decreased use of healthcare resources. However,
the economic benefits of treatment with conventional cor-
ticosteroids in UC may be overestimated in economic
models that failed to take into account the long-term
adverse effects of these medications, such as the increased
risk of osteoporosis and fractures [52]. It remains to be
determined whether the budesonide molecule, or a
particular budesonide formulation, provides an economic
benefit compared with conventional oral corticosteroids,
although the decreased incidence of systemic adverse
effects associated with budesonide may result in long-term
economic benefits.
Patients with UC are often nonadherent to treatment
[53–55], and this has substantial clinical and economic
consequences, including increased risk of UC relapse,
decreased quality of life, and increased healthcare expen-
ditures from hospitalizations and emergency room treat-
ments [56, 57]. Oral formulations of budesonide have
several advantages compared with conventional oral cor-
ticosteroids, including once-daily dosing [15, 16, 42, 58],
targeted absorption in the ileocolonic region or colon (de-
pending on formulation) [39], and favorable AE profiles
[15, 16, 28]. As a result, such formulations may improve
patients’ adherence to therapy. In a study of maintenance
treatment, a greater percentage of UC patients receiving
oral 5-ASA once daily were adherent to treatment after 3
and 6 months compared with patients receiving
Table 2 Most commonly reported adverse events (C5 % of patients in any group) in CORE I and II studies [15, 16]





Placebo Mesalamine 2.4 g Budesonide CIR
9 mg
Any adverse event CORE I 73 (57.5) 74 (58.7) 81 (62.8) 80 (63.0) –
CORE II 71 (55.5) 80 (62.5) 57 (44.2) – 69 (54.8)
UC CORE I 14 (11.0) 15 (11.9) 21 (16.3) 13 (10.2) –
CORE II 20 (15.6) 27 (21.1) 15 (11.6) – 16 (12.7)
Headache CORE I 8 (6.3) 17 (13.5) 19 (14.7) 12 (9.4) –
CORE II 21 (16.4) 20 (15.6) 8 (6.2) – 9 (7.1)
Pyrexia CORE I 3 (2.4) 5 (4.0) 9 (7.0) 3 (2.4) –
CORE II NR NR NR – NR
Insomnia CORE I 5 (3.9) 6 (4.8) 9 (7.0) 3 (2.4) –
CORE II NR NR NR – NR
Back pain CORE I 5 (3.9) 4 (3.2) 7 (5.4) 2 (1.6) –
CORE II NR NR NR – NR
Nausea CORE I 5 (3.9) 5 (4.0) 8 (6.2) 10 (7.9) –
CORE II 8 (6.3) 7 (5.5) 3 (2.3) – 3 (2.4)
Abdominal pain CORE I 6 (4.7) 2 (1.6) 8 (6.2) 10 (7.9) –
CORE II 3 (2.3) 5 (3.9) 7 (5.4) – 7 (5.6)
Diarrhea CORE I 2 (1.6) 5 (4.0) 7 (5.4) 8 (6.3) –
CORE II NR NR NR – NR
Flatulence CORE I 1 (0.8) 1 (0.8) 2 (1.6) 7 (5.5) –
CORE II 5 (3.9) 7 (5.5) 3 (2.3) – 7 (5.6)
Nasopharyngitis CORE I NR NR NR NR –
CORE II 1 (0.8) 8 (6.3) 2 (1.6) – 6 (4.8)
Decreased blood cortisol level CORE I NR NR NR NR –
CORE II 7 (5.5) 3 (2.3) 1 (0.8) – 4 (3.2)
CIR controlled ileocolonic release, CORE Colonic Release Budesonide, MMX multi-matrix, NR not reported, UC ulcerative colitis
Adapted with permission from Sandborn et al. [15] and Travis et al. [16]
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conventional twice-daily or three-times-daily dosing
[3 months: 100 vs. 70 %, respectively (p = 0.04);
6 months: 75 vs. 70 %, respectively (p = 0.8)]. Further-
more, more patients were ‘‘very satisfied’’ with dosing once
daily (83 %) than with dosing twice daily or three times
daily (60 %), although this difference was not statistically
significant [59].
Conclusions
The budesonide MMX formulation delivers the drug
throughout the colon [31], in contrast to other controlled-
release oral formulations of budesonide, which are targeted
to the distal ileum and ascending colon—the sites primarily
affected by inflammation in CD [39]. Budesonide MMX
has been shown to be efficacious and well tolerated for the
induction of remission in patients with mild to moderate
UC [15, 16], and the data currently available suggest that it
may also be efficacious and well tolerated for maintaining
long-term (up to 1 year) UC remission. The long-term
safety of budesonide MMX in patients with UC was
comparable to that of placebo, but these findings are lim-
ited to the single 12-month study [17]. However, several
studies have evaluated the use of oral formulations of
budesonide as maintenance therapy in patients with CD
[18–28], and these have provided support for the long-term
(C1 year) safety of budesonide for maintenance of remis-
sion of inflammatory bowel disease. Budesonide MMX
may also offer pharmacoeconomic benefits by potentially
increasing adherence to treatment via once-daily dosing
and decreasing the risk of AEs compared with conventional
oral corticosteroids. However, more work is needed in this
area.
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